文献速递慢性肾脏病血液净化与透析

度拉糖肽对慢性肾脏病进展相关蛋白的影响

Dulaglutide Effect on Proteins Associated With CKD Progression.
PubMed 文献 · Kidney Int Rep · 2026-01-21

AWARD-7 试验事后分析,比较度拉糖肽与甘精胰岛素治疗 6 个月后 21 种 Joslin 肾脏 Panel 蛋白的变化。度拉糖肽组 14 种蛋白显著降低,尤其 8 种 TNF 受体,提示抗炎抗纤维化机制可能介导肾脏保护。

要点

  • 度拉糖肽治疗 6 个月显著降低 14 种与 ESKD 风险相关的血浆蛋白。
  • 最显著变化为 8 种 TNF 受体,涉及炎症与凋亡通路。
  • 基线 eGFR 较低或 UACR、HbA1c、BMI 较高者治疗效应更明显。

核心结论

  • 度拉糖肽治疗 6 个月显著降低 14 种 JKP 蛋白浓度,尤其炎症和纤维化通路相关蛋白。
  • 这些发现为度拉糖肽肾脏保护作用提供了潜在生物学机制见解。

研究设计与样本

  • AWARD-7 临床试验的事后分析,纳入 2 型糖尿病合并中重度 CKD 参与者。
  • 度拉糖肽组 n=124,甘精胰岛素组 n=125,使用定制 Joslin OLINK 蛋白组学平台检测。
  • 比较基线至 6 个月 21 种 JKP 血浆蛋白浓度的变化。

主要发现

  • 6 个月后,14 种 JKP 蛋白在甘精胰岛素组升高、度拉糖肽组降低,组间差异有统计学意义。
  • 最显著差异为 8 种 TNF 受体(TNF-R1、-R2、-R3、-R4、-R6B、-R7、-R19L、-R27)。
  • CD160、WFDC2、DLL1、LAYN、SYND1、EPHA2 组间差异显著但程度较轻,另 7 种蛋白未受影响。
  • KIM1 在两组均下降,组间无显著差异。
  • 基线 eGFR 较低或 UACR、HbA1c、BMI 较高者治疗效应更明显。

关键数值与推荐

  • 14 种 JKP 蛋白组间差异有统计学意义。
  • 8 种 TNF 受体差异最显著。
  • KIM1 两组均下降但组间无显著差异。

临床怎么用

  • 度拉糖肽可能通过降低炎症和纤维化相关蛋白发挥肾脏保护作用。
  • 对基线 eGFR 较低或 UACR、HbA1c、BMI 较高的 T2D 合并 CKD 患者,度拉糖肽的蛋白调节效应更明显。

局限性

  • 为 AWARD-7 的事后分析,非预设主要终点。
  • 样本量有限(度拉糖肽 n=124,甘精胰岛素 n=125),6 个月随访较短。
  • 蛋白组学发现需进一步验证其与硬终点(如 ESKD)的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the AWARD-7 clinical trial participants with type 2 diabetes mellitus (T2D) and moderate-to-severe chronic kidney disease (CKD), a once-weekly treatment with dulaglutide slowed kidney function decline compared with insulin glargine. This post hoc study evaluated dulaglutide's effect on 6-month changes in plasma concentrations of 21 Joslin Kidney Panel (JKP) proteins, which were previously associated with end-stage kidney disease (ESKD) risk. METHODS: Plasma concentrations of JKP proteins in participants treated with dulaglutide (n = 124) and insulin glargine (n = 125) were measured using a customized Joslin OLINK proteomic platform. Changes in circulating JKP protein concentrations from baseline to 6 months were determined. RESULTS: Baseline JKP protein concentrations were similar between groups. After 6 months, 14 JKP proteins increased in the insulin glargine group and decreased in the dulaglutide group with statistically significant between-group differences. The most significant differences were observed for 8 tumor necrosis factor (TNF)-receptors (TNF-R1, -R2, -R3, -R4, -R6B, -R7, -R19L, and -R27), key mediators of inflammatory and apoptotic pathways. In addition, CD160, WFDC2, DLL1, LAYN, SYND1, and EPHA2 were significantly different between treatments, although to a lesser degree, and 7 other proteins remained unaffected. Kidney injury molecule 1 (KIM1), a marker of proximal tubule stress, declined in both groups without significant differences. Treatment effects were more pronounced in participants with lower baseline estimated glomerular filtration rate or higher baseline urinary albumin-to-creatinine ratio, hemoglobin A1c, or body mass index. CONCLUSION: Six months of dulaglutide treatment significantly lowered concentrations of 14 JKP proteins, particularly those involved in inflammatory and fibrotic pathways. These findings provide insight into biological mechanisms that may underlie the reno-protective effects of dulaglutide.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. McFarlin BE, Tye SC, Satake E, et al. Dulaglutide Effect on Proteins Associated With CKD Progression. Kidney Int Rep. 2026. PMID: 41732754. doi:10.1016/j.ekir.2026.103789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。